Dacogen

(Decitabine)

ApprovedSmall molecule

Decitabine is used to treat certain blood cancers, particularly myelodysplastic syndromes (abnormal blood cell development). It works by helping to restore normal function to blood-forming cells that have become abnormal.[2] Dacogen is currently approved and in use across 62 indications[4].[1]

Dacogen is one of 1141 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Approved.

Indications

316

Total Trials

Active Trials

1,140

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Non-Hodgkins LymphomaApproved

Esophageal Squamous Cell CarcinomaActive, not recruiting

ParagangliomaApproved

Nasopharyngeal CarcinomaApproved

Aplastic AnemiaActive, not recruiting

T-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Lymphoblastic LymphomaActive, not recruiting

Unspecified Peripheral T-Cell LymphomaApproved

ThrombocytopeniaActive, not recruiting

LymphomaApproved

Non-Hodgkins LymphomaApproved

Approved

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

ParagangliomaApproved

Approved

Nasopharyngeal CarcinomaApproved

Approved

Aplastic AnemiaPhase 2

Active, not recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Lymphoblastic LymphomaApproved

Active, not recruiting

Unspecified Peripheral T-Cell LymphomaApproved

Approved

ThrombocytopeniaPhase 3

Active, not recruiting

LymphomaApproved

Approved

Showing 10 of 62 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Dacogen

Sun Pharma

Approved

316 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Acupan

YYonsei University

Preclinical

1 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Paracetamol

GSK

Preclinical

1 9

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Myelodysplastic Syndrome

NCT02890329

Q4 2026

Phase 2/3Recruiting

Acute Leukemia

NCT03793517

Phase 3Not yet recruiting

Poor Graft Function

NCT05669079

Phase 2Active, not recruiting

High Risk

NCT04097470

Phase 3Not yet recruiting

Poor Graft Function

NCT05907499

Phase 2Recruiting

Blast Phase Myeloproliferative Neoplasm

NCT04282187

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia36 trials

AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia

Completed·AAlison Walker·Phase 1·NCT01798901·13 enrolled

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT02029417·2 enrolled

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·CCyclacel Pharmaceuticals, Inc.·Phase 3·NCT01303796·482 enrolled

Show 33 more trials

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1/2·NCT02632721·49 enrolled

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Terminated· Pfizer logo

Pfizer·Phase 3·NCT02785900·240 enrolled

Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00703300·19 enrolled

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Completed·BBhavana Bhatnagar·Phase 1·NCT02323607·13 enrolled

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

Withdrawn·—·Phase 1·NCT04655391

Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia

Completed·UUniversity Hospital Freiburg·Phase 2·NCT00867672·204 enrolled

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Terminated·DDavid Iberri·Phase 2·NCT01846624·13 enrolled

Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia

Unknown status·CChunyan Ji·Phase 3·NCT02985372·30 enrolled

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

Terminated· Pfizer logo

Pfizer·Phase 1·NCT02954653·8 enrolled

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·BBhavana Bhatnagar·Phase 1·NCT02093403·25 enrolled

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT02996474·10 enrolled

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial

Unknown status·HHuihan Wang·Phase 3·NCT05382390·130 enrolled

Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00492401·55 enrolled

Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Suspended· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT04485052·222 enrolled

Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2/3·NCT00398983·50 enrolled

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Terminated·KKartos Therapeutics, Inc.·Phase 1/2·NCT04113616·70 enrolled

Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01786343·74 enrolled

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Terminated·WWashington University School of Medicine·Phase 2·NCT03063203·17 enrolled

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·EECOG-ACRIN Cancer Research Group·Phase 3·NCT02085408·727 enrolled

A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·UUniversity of Rochester·Phase 1·NCT00861874·13 enrolled

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03041688·58 enrolled

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Recruiting·BBrian Jonas·Phase 2·NCT04905810·20 enrolled

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

Completed·WWeill Medical College of Cornell University·Phase 1·NCT01352650·71 enrolled

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT03063944·37 enrolled

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Terminated·SSanjay Mohan·Phase 2·NCT05799079·1 enrolled

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03164057·206 enrolled

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT02257138·30 enrolled

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

Active, not recruiting·—·Phase 1·NCT03009240·30 enrolled

Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)

Terminated· Gilead logo

Gilead·Phase 1/2·NCT02343939·148 enrolled

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06401603·30 enrolled

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Completed·RRutgers, The State University of New Jersey·Phase 2·NCT04146038·5 enrolled

Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients

Unknown status·JJianxiang Wang·Phase 3·NCT01633099·46 enrolled

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT01707004·20 enrolled

Myelodysplastic Syndrome31 trials

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Completed·—·Phase 1/2·NCT01165996·25 enrolled

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed· Eisai logo

Eisai·Phase 2·NCT00760084·10 enrolled

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

Completed· Amgen logo

Amgen·Phase 2·NCT00321711·69 enrolled

Show 28 more trials

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Recruiting·—·Phase 1·NCT03969446·54 enrolled

Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)

Suspended·SSclnow Biotechnology Co., Ltd.·Phase 1/2·NCT03184935·40 enrolled

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

Completed·UUniversity of Washington·N/A·NCT02121418·12 enrolled

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02890329·54 enrolled

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00801489·270 enrolled

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT03092674·76 enrolled

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

Unknown status·SShanghai Tong Ren Hospital·Phase 2·NCT03356080·50 enrolled

Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01893320·66 enrolled

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

No longer available· Johnson & Johnson logo

Johnson & Johnson··NCT01026376

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00882102·43 enrolled

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01834248·9 enrolled

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1·NCT03358719·8 enrolled

An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)

Completed·JJohnson & Johnson Taiwan Ltd·Phase 2·NCT00744757·37 enrolled

Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure

Unknown status·KKing's College London·Phase 2·NCT01133886·50 enrolled

Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01720225·113 enrolled

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00043134·220 enrolled

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03661307·73 enrolled

Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02141477·2 enrolled

Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant

Completed·WWashington University School of Medicine·Phase 1·NCT00986804·24 enrolled

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Recruiting·SSyntrix Biosystems, Inc.·Phase 1·NCT04245397·151 enrolled

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02010645·6 enrolled

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed· Pfizer logo

Pfizer·Phase 2·NCT01546038·255 enrolled

Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT01809392·15 enrolled

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01515527·160 enrolled

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Active, not recruiting·TThomas Jefferson University·Phase 1·NCT05564650·6 enrolled

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00067808·128 enrolled

Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

Withdrawn·LLi Junmin·Phase 3·NCT03377725

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03404193·235 enrolled

Myelodysplastic Syndromes14 trials

A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT02779569·80 enrolled

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00075010·54 enrolled

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Completed· Eisai logo

Eisai·Phase 2·NCT00619099·67 enrolled

Show 11 more trials

Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Completed·WWashington University School of Medicine·Phase 2·NCT01687400·114 enrolled

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT01729845·52 enrolled

Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02469415·3 enrolled

Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

Completed·WWashington University School of Medicine·Phase 1·NCT00671697·13 enrolled

Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes

Recruiting·WWest Virginia University·Phase 1/2·NCT06923488·26 enrolled

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00382200·54 enrolled

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00903760·42 enrolled

Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00049582·36 enrolled

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

Withdrawn· Takeda logo

Takeda·Phase 2·NCT04985656

Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01593670·9 enrolled

A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)

Recruiting·TTreebough Therapies·Phase 1·NCT07006025·20 enrolled

Lymphoma9 trials

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Recruiting·—·Phase 1/2·NCT04337606·100 enrolled

Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas

Unknown status·HHan weidong·Phase 1/2·NCT01799083·100 enrolled

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Unknown status·SSouthwest Hospital, China·Phase 3·NCT03553537·100 enrolled

Show 6 more trials

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Unknown status·—·Phase 2·NCT04233294·100 enrolled

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Unknown status·—·Phase 2·NCT04279379·20 enrolled

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

Unknown status·—·Phase 2·NCT03250962·280 enrolled

A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

Unknown status·MMingzhi Zhang·Phase 4·NCT03579082·60 enrolled

Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00109824·42 enrolled

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00089089·42 enrolled

Leukemia8 trials

Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)

Completed·WWashington University School of Medicine·Phase 1·NCT01001143·19 enrolled

A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00349596·40 enrolled

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

Completed·FFox Chase Cancer Center·Phase 2·NCT02190695·92 enrolled

Show 5 more trials

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03132454·32 enrolled

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Terminated· AbbVie logo

AbbVie·Phase 1·NCT02203773·212 enrolled

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04874480·9 enrolled

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT07044544·20 enrolled

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Terminated· Eisai logo

Eisai·Phase 2·NCT01177540·25 enrolled

73 more indications

Conditioning4 trials

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Completed·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT02744742·202 enrolled

10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

Completed·RRadboud University Medical Center·Phase 2·NCT02252107·46 enrolled

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT04123392·196 enrolled

Show 1 more trial

Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03530085·60 enrolled

Ovarian Cancer4 trials

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

Not yet recruiting·UUniversity of Chicago·Phase 1/2·NCT07389239·24 enrolled

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Recruiting·LLoyola University·Phase 2·NCT05983276·40 enrolled

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03467178·119 enrolled

Show 1 more trial

Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer

Completed·IIndiana University·Phase 1/2·NCT00477386·28 enrolled

Acute Leukemia3 trials

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Recruiting·PPeking University People's Hospital·Phase 2/3·NCT03793517·55 enrolled

Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03596892·122 enrolled

Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

Unknown status·PPeking University People's Hospital·Phase 2/3·NCT03799224·55 enrolled

Relapsed or Refractory3 trials

Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT04493099

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT01607645·7 enrolled

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Recruiting·HHan weidong·Phase 1/2·NCT02961101·250 enrolled

Efficacy and Safety3 trials

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

Not yet recruiting·RRuijin Hospital·Phase 3·NCT06297772·220 enrolled

Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent

Unknown status·SShandong University·Phase 2·NCT03045510·50 enrolled

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Recruiting·RRuijin Hospital·Phase 2·NCT06803693·152 enrolled

MDS3 trials

To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.

Terminated· Eisai logo

Eisai·Phase 4·NCT01011283·26 enrolled

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Terminated· Novartis logo

Novartis·Phase 2·NCT04878432·39 enrolled

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Active, not recruiting·—·Phase 1·NCT03974217·13 enrolled

Allogeneic Hematopoietic Cell Transplant2 trials

Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS Patients

Terminated·SSingapore General Hospital·Phase 2·NCT01333449·6 enrolled

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Withdrawn·—·Phase 1·NCT06572631

Chronic Myelogenous Leukemia2 trials

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00054431·80 enrolled

Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00002832·14 enrolled

Chemotherapy2 trials

Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice

Unknown status·UUlsan University Hospital··NCT02698124·136 enrolled

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Recruiting· Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.·Phase 3·NCT05586074·324 enrolled

Newly Diagnosed2 trials

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT06429098·40 enrolled

Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60

Terminated·EEmory University·Phase 1·NCT02234037·3 enrolled

Poor Graft Function2 trials

Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT05669079·100 enrolled

Decitabine for Poor Graft Function Post Allo-HSCT

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT05907499·76 enrolled

Treatment2 trials

Genotype-guided Treatment in DLBCL

Recruiting·RRuijin Hospital·Phase 3·NCT05351346·1,100 enrolled

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

Completed·JJohn Mascarenhas·Phase 1/2·NCT02076191·49 enrolled

Fallopian Tube Cancer2 trials

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01673217·18 enrolled

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1·NCT03017131·9 enrolled

High Risk2 trials

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Completed· Novartis logo

Novartis·Phase 1·NCT03066648·241 enrolled

Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

Active, not recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 2·NCT04097470·140 enrolled

Blast Phase Myeloproliferative Neoplasm2 trials

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Recruiting·UUniversity of Washington·Phase 2·NCT04282187·25 enrolled

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Recruiting·UUniversity of Washington·Phase 2·NCT07148947·27 enrolled

Acute Lymphoblastic Leukemia2 trials

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00882206·15 enrolled

Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00042796·21 enrolled

Stem Cell Transplant2 trials

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Withdrawn·NNorthside Hospital, Inc.·Phase 2·NCT06337331

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Recruiting·FFred Hutchinson Cancer Center·Phase 1/2·NCT06928662·36 enrolled

Melanoma2 trials

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00791271·17 enrolled

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

Completed·CCalifornia Cancer Consortium·Phase 1·NCT00002980

Myelofibrosis2 trials

Study of Select Combinations in Adults With Myelofibrosis

Withdrawn· Novartis logo

Novartis·Phase 1·NCT04283526

Decitabine in Treating Patients With Myelofibrosis

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT00095784·21 enrolled

Pancreatic Cancer2 trials

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Completed·YYogen Saunthararajah·Phase 1·NCT02847000·13 enrolled

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Completed·MMohammed Milhem·Phase 1·NCT02959164·36 enrolled

Pembrolizumab1 trial

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

Completed·—·Phase 1·NCT03445858·22 enrolled

Combination Therapy1 trial

Clinical Study of Decitabine and Paclitaxel Combination Therapy

Unknown status·DDong Wha Pharmaceutical Co. Ltd.·Phase 1·NCT03282825·18 enrolled

Myeloid Malignancies1 trial

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06930651·42 enrolled

Carboplatin1 trial

Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC

Terminated·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT03295552·12 enrolled

Adult Subject1 trial

Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects

Completed·EEpiDestiny, Inc.·Phase 1·NCT04086238·46 enrolled

Outcome1 trial

Outcomes of Patients After Allo-HSCT With Decitabine and NAC

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT04945096·100 enrolled

Phase 21 trial

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

Completed·HHelsinn Healthcare SA·Phase 2·NCT01993641·45 enrolled

Induction Chemotherapy1 trial

Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML

Completed·WWeill Medical College of Cornell University·Phase 1·NCT00538876·30 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·RRuijin Hospital·Phase 2/3·NCT06972641·126 enrolled

Relapsed/Refractory AML1 trial

Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML

Recruiting·UUniversity Hospital Tuebingen·Phase 2·NCT06156579·27 enrolled

Relapsed/Refractory1 trial

Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

Unknown status·—·Phase 1/2·NCT03346642·30 enrolled

Sickle Cell Disease1 trial

Decitabine for High-Risk Sickle Cell Disease

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT01375608·10 enrolled

Lymphoid Malignancies1 trial

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Completed·YYogen Saunthararajah·Phase 1·NCT02846935·7 enrolled

Myeloid Neoplasm1 trial

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

Completed·HHospital Israelita Albert Einstein·Phase 2·NCT02084563·455 enrolled

Juvenile Myelomonocytic Leukemia1 trial

Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia

Unknown status·—··NCT03687463·6 enrolled

Immune Thrombocytopenia1 trial

A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia

Completed·SShandong University·Phase 2·NCT01568333·45 enrolled

Hematological Malignancies1 trial

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Withdrawn·PPrincess Maxima Center for Pediatric Oncology·Phase 1/2·NCT05740449

Pilot Study1 trial

Pilot Study of Reduced Venetoclax Exposure

Recruiting·NNorthwell Health·Phase 2·NCT07163793·41 enrolled

Relapse1 trial

Epigenetic Reprogramming in Relapse AML

Terminated·MMichael Burke·Phase 1·NCT02412475·3 enrolled

Prostate Cancer1 trial

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Withdrawn·RRoswell Park Cancer Institute·Phase 1/2·NCT03709550

Patients With Advanced Solid Tumors1 trial

Decitabine in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00030615·24 enrolled

Refractory AML1 trial

Epigenetic Reprogramming in Relapse/Refractory AML

Completed·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT03263936·37 enrolled

Colon Cancer1 trial

Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study

Terminated·—·N/A·NCT01882660·10 enrolled

Thalassemia1 trial

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

Completed·CCarelon Research··NCT00000623·1,000 enrolled

Malignant Mesothelioma1 trial

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00019825

Thrombocytopenia1 trial

Prospective Study of Patients With Thrombocytopenia Following HSCT

Completed·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT02487563·97 enrolled

Trial1 trial

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Terminated·DDelta-Fly Pharma, Inc.·Phase 3·NCT03926624·167 enrolled

Adult AML1 trial

Safety and Activity of Digoxin With Decitabine in Adult AML and MDS

Terminated·FFox Chase Cancer Center·Phase 1/2·NCT03113071·1 enrolled

Maintenance Treatment1 trial

Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML

Unknown status·SSeoul St. Mary's Hospital·Phase 1·NCT01277484·19 enrolled

Decitabine-primed Tandem CD19/CD20 CAR T Cells1 trial

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Unknown status·—·Phase 1/2·NCT04553393·80 enrolled

Older Patients1 trial

Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT02532010·13 enrolled

Frontline1 trial

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Withdrawn·UUniversity of Florida·Phase 2·NCT05766514

Thyroid Cancer1 trial

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00085293·12 enrolled

Solid Tumors1 trial

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03875287·35 enrolled

Malignant Tumors1 trial

Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

Unknown status·LLi Yu·Phase 3·NCT04292769·200 enrolled

Allogeneic Stem Cell Transplantation1 trial

Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation

Completed·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT03663751·14 enrolled

Oral1 trial

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

Completed·EEpiDestiny, Inc.·Phase 1·NCT05816356·10 enrolled

Myeloproliferative Disorder1 trial

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00114257·36 enrolled

Age1 trial

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06511882·37 enrolled

Non-Small Cell Lung Cancer1 trial

Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00084981·25 enrolled

Immune Checkpoint Inhibitors1 trial

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Unknown status·—·Phase 1/2·NCT05320640·100 enrolled

AML/MDS1 trial

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT04055844·14 enrolled

Hematopoietic Stem Cell Transplant1 trial

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Recruiting·FFranziska Wachter·Phase 2·NCT05796570·37 enrolled

Advanced Hematologic Malignancies1 trial

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Active, not recruiting·FFoghorn Therapeutics Inc.·Phase 1·NCT04891757·144 enrolled

Efficacy1 trial

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06441097·152 enrolled

Chronic Lymphocytic Leukemia1 trial

Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00079378·84 enrolled

Advanced Malignancies1 trial

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Terminated· Novartis logo

Novartis·Phase 1/2·NCT02608268·252 enrolled

Malignancies1 trial

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00037817·34 enrolled

Untreated AML1 trial

Decitabine and Talazoparib in Untreated AML and R/R AML

Completed·UUniversity of Maryland, Baltimore·Phase 1/2·NCT02878785·25 enrolled

Acute Respiratory Distress Syndrome1 trial

Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial

Suspended·JJohns Hopkins University·Phase 2·NCT04482621·33 enrolled

Phase IB1 trial

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Completed·BBerGenBio ASA·Phase 1/2·NCT02488408·122 enrolled

Randomized1 trial

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

Completed·GGroupe Francophone des Myelodysplasies·Phase 3·NCT02214407·170 enrolled

Unspecified2 trials

Avapritinib With Decitabine in Patients With SM-AHN

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06327685·34 enrolled

Phase I, Dose Escalation Study of Decitabine

Completed·UUniversity of Florida·Phase 1·NCT02264873·3 enrolled

Regulatory

FDA Approval Timeline[5]

May 2, 2006

DACOGEN

NDA NDA021790

Jan 28, 2014

DECITABINE

NDA NDA205582

Sources

References

[1]
ClinicalTrials.gov — 316 trial records for Decitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Dacogen drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Decitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Decitabine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA205582). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Sun Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA (cytosine-5)-Methyltransferase 1 Inhibitor; DNA (cytosine-5)-Methyltransferase 3a Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Sun Pharma